Advance one process architecture, scale, facility, campaign or transfer option only after product quality, process robustness, equipment fit, finite resources, economics, environmental inventory and validation evidence remain consistent.
Independent company use-case study · biopharmaceutical CDMO
Samsung BiologicsFive process decisions
Choose one use case. Add authorised plant data. Test capacity, cost and constraints.
Decision brief
One question. One model.
Authorised mammalian or other starting basis through cultivation, harvest, filtration, chromatography, concentration, formulation and relevant fill-finish, including cleaning, utilities, quality holds, waste, transfer and accepted product.
Five practical use cases
Five places to start.
Evaluation scopes for Samsung Biologics—not claims of current software use.Compare complete biologics process architectures
Connect cultivation, harvest, filtration, chromatography, concentration and formulation on one material, quality, equipment, time and uncertainty basis before selecting the next authorised study.
Screen scale-up, transfer and facility fit
Translate authorised development or scale-down evidence into mixing, gas-transfer, heat-removal and downstream-load envelopes, then test requirements against approved target equipment and utilities.
Test multi-product CDMO campaigns offline
Schedule eligible upstream, downstream, buffer, fill-finish, cleaning, laboratory and release resources without representing Samsung Biologics customers, real capacity, occupancy or delivery commitments.
Compare process and facility TEA/LCA scenarios
Evaluate intensity, single-use, facility or supply options across yield, materials, energy, water, waste, capital and operating cost under the same functional unit and boundary.
Govern technology-transfer and validation evidence
Link process history, scale assumptions, critical parameters, analytical methods, risks, engineering and GMP runs, deviations and acceptance criteria without performing formal validation.
Action pack
Inputs in. Decisions out.
- Molecule, modality, cell platform, quality and demand basis
- Growth, titer, recovery, process and scale-down evidence
- Equipment eligibility, scale rules, hold times and facility limits
- Materials, consumables, utilities, waste, cost and lifecycle factors
- End-to-end process-architecture comparison
- Scale-up and facility-fit evidence map
- Finite campaign schedule and accepted-capacity range
- TEA/LCA screen and transfer-validation register
- Select one customer-authorised process or transfer decision.
- Declare product, quality, facility and transfer boundaries.
- Import development, scale-down and equipment evidence.
Evidence and limits
Public evidence only.
- Samsung Biologics — Articles of IncorporationOfficial legal context for the English company name, registered office and stated business purposes.
- Samsung Biologics — Pure-play CDMO spin-offOfficial current company boundary after Samsung Epis Holdings and Samsung Bioepis were separated in November 2025.
- Samsung Biologics — MilestonesOfficial current context for the pure-play CDMO transition, manufacturing expansion and Samsung Biologics' own ExellenS framework.
- Samsung Biologics — Global locationsOfficial context for the current global CDMO manufacturing and office network supporting scale-up and technology transfer.
- Samsung Biologics — Process developmentOfficial context for the company's own QbD, DoE, upstream, downstream and formulation-development services.
- Samsung Biologics — ExellenS frameworkOfficial context for the company's own standardised facility, equipment, process and digital platform framework.
Guardrail: No Samsung Biologics customer, molecule, process, site, campaign, capacity, occupancy, yield, cost, environmental result, deployment or digital system is represented. Technology transfer, validation, PPQ, GxP, batch release, regulatory and commercial decisions remain under approved company and customer systems.